Biologic Therapies for Discogenic Pain

Area of Science:

• Regenerative Medicine
• Orthopedics
• Pain Management

Background:

• Discogenic back pain is a significant source of disability.
• Biologic therapies are emerging as potential treatments.
• Platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) are key biologics.

Purpose of the Study:

• To review recent advancements in regenerative medicine for discogenic back pain.
• To focus on biologics, including PRP and MSCs.
• To evaluate current evidence on their safety and efficacy.

Main Methods:

• Review of recent literature and studies on biologics for discogenic back pain.
• Analysis of emerging data on platelet-rich plasma and mesenchymal cells.
• Assessment of study designs and reported outcomes.

Main Results:

• Significant increase in research interest and publications on biologics for back pain.
• Generally uncommon serious adverse events, but study designs vary widely.
• Need for more robust investigations to confirm safety and efficacy.
• Understanding of disc degeneration mechanisms requires further research.

Conclusions:

• Biologics show potential for treating discogenic pain.
• More multi-center, prospective, double-blinded, randomized placebo-controlled trials are essential.
• Continued research and funding are crucial for developing targeted therapies.